Journal Mobile Options
Table of Contents
Vol. 40, No. 1, 2008
Issue release date: December 2007
Section title: Original Paper
Ophthalmic Res 2008;40:10–15
(DOI:10.1159/000111152)

Olmesartan Blocks Inflammatory Reactions in Endothelial Cells Evoked by Advanced Glycation End Products by Suppressing Generation of Reactive Oxygen Species

Yamagishi S. · Matsui T. · Nakamura K. · Inoue H. · Takeuchi M. · Ueda S. · Okuda S. · Imaizumi T.
Divisions of aCardiovascular Medicine and bNephrology, Department of Medicine, and cRadioisotope Institute for Basic and Clinical Medicine, Kurume University School of Medicine, Kurume, and dDepartment of Pathophysiological Science, Faculty of Pharmaceutical Science, Hokuriku University, Kanazawa, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 3/29/2007
Accepted: 5/17/2007
Published online: 11/20/2007

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 0

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE

Abstract

Background/Aims: We have previously shown that interaction between advanced glycation end products (AGEs) and their receptor (RAGE) evokes generation of reactive oxygen species (ROS) and subsequently vascular inflammation, thus being involved in the development of diabetic retinopathy. Since there is crosstalk between the AGE-RAGE axis and the renin-angiotensin system in the pathogenesis of early diabetic retinopathy, we investigated in this study whether olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked inflammatory reactions in endothelial cells (ECs) by suppressing ROS generation. Methods: ROS generation was evaluated by dihydroethidium staining. Gene and protein expression were analyzed by reverse-transcription polymerase chain reaction and ELISA, respectively. Results: Olmesartan significantly inhibited the AGE-evoked ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 in microvascular ECs. Olme-sartan also suppressed intercellular-adhesion molecule 1 expression in, and subsequently blocked T-cell adhesion to, AGE-exposed ECs. Conclusions: The present study demonstrates for the first time that olmesartan inhibits AGE-evoked inflammatory reactions in ECs by suppressing ROS generation. Blockade of the renin-angiotensin system by olmesartan may play a protective role against diabetic retinopathy by attenuating the deleterious effects of AGEs through its antioxidative properties.


  

Author Contacts

Dr. Sho-ichi Yamagishi
Department of Medicine, Kurume University School of Medicine
67 Asahi-machi
Kurume 830-0011 (Japan)
Tel. +81 942 31 7580, Fax +81 942 31 7707, E-Mail shoichi@med.kurume-u.ac.jp

  

Article Information

Received: March 29, 2007
Accepted after revision: May 17, 2007
Published online: November 20, 2007
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 0, Number of References : 28

  

Publication Details

Ophthalmic Research (Journal for Research in Experimental and Clinical Ophthalmology)

Vol. 40, No. 1, Year 2008 (Cover Date: December 2007)

Journal Editor: Pleyer, U. (Berlin)
ISSN: 0030–3747 (print), 1423–0259 (Online)

For additional information: http://www.karger.com/ORE


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 3/29/2007
Accepted: 5/17/2007
Published online: 11/20/2007

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 0

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.